Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Background: Treatment of cancers with programmed cell death protein 1 (PD-1) pathway inhibitors can lead to immune-related adverse events (irAEs), which could be serious and even fetal. Therefore, clinicians should be aware of the characteristics of irAEs associated with the use of such drugs.Method...

Full description

Bibliographic Details
Main Authors: Peng-Fei Wang, Yang Chen, Si-Ying Song, Ting-Jian Wang, Wen-Jun Ji, Shou-Wei Li, Ning Liu, Chang-Xiang Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-10-01
Series:Frontiers in Pharmacology
Subjects:
Anti-PD-1 antibodies
immune-related adverse events
immunotherapy
oncology
nivolumab
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00730/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00730/full

Similar Items